C-Path’s Neuroscience Program hosted its first webinar on August 17, 2021. This webinar brought together more than 330 members, representatives and partners from pharmaceutical industries, academic experts, government and regulatory agencies, and patient advocacy groups.

Dr. Terina Martinez, Executive Director of the Critical Path to Therapeutics for the Ataxias (CPTA) and Duchenne Regulatory Science Consortium (D-RSC) provided a presentation on neurofilament light chain (NfL) in neurodegenerative diseases. Dr. Martinez presented an overview on NfL assay and clinical validity, NfL biomarker case studies, and current challenges and unaddressed questions for NfL as a clinical trial-ready biomarker, followed by a robust panel discussion, led by subject matter experts: Henrik Zetterberg, MD, PhD, Matthis Synofzik, MD, and Samantha Hutten, PhD.